Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma
FL Locke, JM Rossi, SS Neelapu… - Blood …, 2020 - ashpublications.org
ZUMA-1 demonstrated a high rate of durable response and a manageable safety profile with
axicabtagene ciloleucel (axi-cel), an anti-CD19 chimeric antigen receptor (CAR) T-cell …
axicabtagene ciloleucel (axi-cel), an anti-CD19 chimeric antigen receptor (CAR) T-cell …
CAR‐T TREK through the lymphoma universe, to boldly go where no other therapy has gone before
G Ghilardi, P Braendstrup, EA Chong… - British Journal of …, 2021 - Wiley Online Library
Chimeric antigen receptor (CAR) T cells (CART) therapies have changed and continue to
change the treatment paradigms for B‐cell malignancies because they can achieve durable …
change the treatment paradigms for B‐cell malignancies because they can achieve durable …
[HTML][HTML] Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy
PH Chen, M Lipschitz, JL Weirather, C Jacobson… - JCI insight, 2020 - ncbi.nlm.nih.gov
Mechanisms of chimeric antigen receptor (CAR) T cell–mediated antitumor immunity and
toxicity remain poorly characterized because few studies examine the intact tumor …
toxicity remain poorly characterized because few studies examine the intact tumor …
Exploration of tumor biopsy gene signatures to understand the role of the tumor microenvironment in outcomes to lisocabtagene maraleucel
In the TRANSCEND NHL 001 study, 53% of patients with relapsed/refractory large B-cell
lymphoma (LBCL) treated with lisocabtagene maraleucel (liso-cel) achieved a complete …
lymphoma (LBCL) treated with lisocabtagene maraleucel (liso-cel) achieved a complete …
Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd–3rd, 2020, Italy)
Improved understanding of tumor immunology has enabled the development of therapies
that harness the immune system and prevent immune escape. Numerous clinical trials and …
that harness the immune system and prevent immune escape. Numerous clinical trials and …
[PDF][PDF] The Role of Tumor Microenvironment in T Cell Redirecting Therapies of Large B Cell Lymphoma: Translating Lessons Learned from CAR-T to Bispecific …
KV Lepik, VV Markelov - 2024 - preprints.org
T-cell redirecting therapies, which include chimeric antigen receptor T-cells (CAR-T) and
bispecific antibodies (BSAs), have revolutionized the treatment of relapsed\refractory large B …
bispecific antibodies (BSAs), have revolutionized the treatment of relapsed\refractory large B …
Cellules T à récepteur antigénique chimérique: limites actuelles et développements à venir.
M Alcantara, R Houot - Hematologie, 2020 - search.ebscohost.com
Les cellules T à récepteur antigénique chimérique (CAR-T) représentent une avancée
thérapeutique majeure en oncohématologie. À ce jour, deux CAR-T anti-CD19 ont été …
thérapeutique majeure en oncohématologie. À ce jour, deux CAR-T anti-CD19 ont été …
CAR T-cells: current limitations and future developments
M Alcantara, R Houot - Hématologie, 2020 - jle.com
Chimeric antigen receptor (CAR) T-cells represent a great breakthrough in the treatment of
hematologic malignancies. To date, two different CAR T-cells have been approved for the …
hematologic malignancies. To date, two different CAR T-cells have been approved for the …